Epicenter Health Research
About Company
Epicentre’s Uganda Research Centre conducts health related research aimed at influencing policy globally and relevant to Africa and Uganda in particular.
The Mbarara Research Centre laboratory in Uganda is GCLP (Good Clinical Laboratory Practice) accredited by the international and independent accreditation system, Qualogy. Studies are conducted according to Good Clinical Practice and Good Clinical and Laboratory Practice quality standards. Epicentre collaborates closely with the Mbarara University of Science and Technology (MUST), the Mbarara Regional Referral Hospital (MRRH), the Ministry of Health and other stakeholders in research, academia and the health sector.
The centre has an experienced team of medical doctors, nurses, social workers, statisticians, biologists, laboratory technicians, information technology scientists, logisticians, and administrators who ensure the quality of the research.
Epicentre research has contributed to public health policy changes including the seminal AQUAMAT trial that demonstrated that artesunate significantly reduces mortality in African children with severe malaria. Current projects continue to focus on improving diagnosis and therapies for infectious diseases such as tuberculosis, HIV, central nervous system infections, as well as vaccines trials on Ebola and Yellow fever.
Video
With regard to tuberculosis, the center is involved in several large-scale projects. It is one of the sites of the TB-Speed study coordinated by Université de Bordeaux, which aims to reduce infant mortality due to tuberculosis. This infectious disease remains one of the main causes of death in children under 5 years of age and most of them die without having access to treatment because they are often not diagnosed. The goal of the TB-Speed study is to identify rapid, effective, and easy-to-use diagnostic tests to improve the diagnosis of TB in children.
The Mbarara Center is also collaborating in international treatment trials to simplify or reduce treatment regimens, which currently involve taking medication daily for 6 to 8 months. If treatment could be reduced to 3 or even 4 months, it would improve compliance and daily life for patients while limiting the emergence of drug resistance. After several previous studies, the international Rifashort trial is evaluating the efficacy and safety of a 4-month regimen using double and triple doses of rifampicin. The EDCTP and ANRS-funded DATURA trial is comparing the efficacy of more intensive initial treatment of TB with higher doses of the main antibiotics used, rifampicin and isoniazid, plus corticosteroids, in hospitalized adults and adolescents co-infected with HIV and TB versus standard treatment.
The Center also included the first patient in the DNDi-coordinated “LOLIPOP” study, which evaluated the 4-in-1 treatment for children with HIV in Uganda. This treatment combines four drugs needed to treat pediatric HIV in a single pellet-filled capsule that is easy to use, heat stable, tasteless, solid, and does not contain alcohol or inappropriate solvents.
